HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Consumer Health Industry, Pandemic-Driven Buying Reveals Signs For Sustaining Sales Growth

Executive Summary

"It's a great industry to be in with it being pandemic proof," says Natural Marketing Institute managing partner Steve French. "Consumers really want one-stop shopping in this situation. They want stores they can get into and get out of it," says IRI health care executive Kristin Hornberger.

You may also be interested in...



Pandemic-Driven Trends Show Strong Immunity Supplement Future, Elderberry A Current 'Darling'

VMS, homeopathic and other natural producs firms couldn't plan for spike in demand from coronavirus 2019, but the pandemic provides information to continue riding heightened consumer interest to higher ongoing sales, researchers said in recent Council for Responsible Nutrition webinar.

Cannabidiol Safety In Question At US FDA? Exploding Market Suggests Not So Much

A report FDA submitted to Congress earlier in March on determining an enforcement discretion policy for CBD-containing non-drug products did little to indicate it is approaching a decision. It's likely that FDA officials are reasonably confident of CBD's safety in food and supplements because the agency has allowed the market to proliferate.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel